Naturally, since a lot more patients received Temodar than DCVax-L and GBM is a terminal illness so with both drugs the majority of recipients die and since few get DCVax-L of course one can say more patients die who take Temodar because more patients take Temodar.
Temodar was a lot better than nothing which is pretty much what it replaced and it offered life extension, not a cure (maybe in the rate case GBM was caught super early could be cured with resection as well, maybe).
DCVax-L offers some patients an effective cure and thus unlike Temodar one could do the grim math and measure a cost in lives for each year or delay in getting it to market by extrapolating from the Phase 3 trial data. I don’t need to get any angrier at this management team but I’m sure someone else can take up the challenge.
News 
Market Data 
Discover 
